Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Ensysce Biosciences (ENSC) over the last 5 years, with Q3 2025 value amounting to $102785.0.

  • Ensysce Biosciences' Gains from Investment Securities fell 8231.85% to $102785.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $102785.0, marking a year-over-year decrease of 8231.85%. This contributed to the annual value of $38785.0 for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Ensysce Biosciences' Gains from Investment Securities stood at $102785.0, which was down 8231.85% from $102785.0 recorded in Q2 2025.
  • Ensysce Biosciences' 5-year Gains from Investment Securities high stood at $6.7 million for Q2 2022, and its period low was $1600.0 during Q1 2021.
  • For the 5-year period, Ensysce Biosciences' Gains from Investment Securities averaged around $1.1 million, with its median value being $96785.0 (2025).
  • In the last 5 years, Ensysce Biosciences' Gains from Investment Securities tumbled by 9264.77% in 2022 and then surged by 210914.34% in 2024.
  • Over the past 5 years, Ensysce Biosciences' Gains from Investment Securities (Quarter) stood at $4.4 million in 2021, then plummeted by 98.69% to $58435.0 in 2022, then tumbled by 33.63% to $38785.0 in 2023, then changed by 0.0% to $38785.0 in 2024, then skyrocketed by 165.01% to $102785.0 in 2025.
  • Its Gains from Investment Securities was $102785.0 in Q3 2025, compared to $102785.0 in Q2 2025 and $90785.0 in Q1 2025.